Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CSPC OUYI PHARMACEUTICAL CO., LTD.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2001-03-29

Employees: -

Market Cap: -

Website: http://www.e-cspc.com

Clinical Trials

A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Phase 3

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
Drug: Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
Drug: Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR
Drug: Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
Drug: Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR

First Posted Date: 2025-06-18

Last Posted Date: 2025-06-18

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 815

Registration Number: NCT07026968

A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder

Phase 3

Recruiting

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Dextromethorphan and Bupropion Sustained-Release Tablets
Drug: Placebo

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 388

Registration Number: NCT06958692

Locations: 🇨🇳
Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Phase 3

Not yet recruiting

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: SYHX1901

First Posted Date: 2025-04-25

Last Posted Date: 2025-04-30

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 500

Registration Number: NCT06943950

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Liposomal Irinotecan
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Capecitabine
Drug: S-1

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-27

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 408

Registration Number: NCT06571461

A Phase II Study of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata

Phase 2

Not yet recruiting

Conditions: Severe Alopecia Areata

Interventions: Drug: SYHX1901
Drug: Placebo

First Posted Date: 2024-08-20

Last Posted Date: 2025-06-03

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT06562894

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Phase 2

Recruiting

Conditions: Non-segmental Vitiligo

Interventions: Drug: SYHX1901
Drug: placebo

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 144

Registration Number: NCT06511739

Locations: 🇨🇳
Clinical Trials Information Group, Shijiazhuang, China

Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia

Phase 3

Not yet recruiting

Conditions: Presbyopia

Interventions: Drug: Vehicle
Drug: Pilocarpine HCl Ophthalmic Solution

First Posted Date: 2024-06-11

Last Posted Date: 2024-07-03

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 330

Registration Number: NCT06451666

A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy

Phase 3

Not yet recruiting

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: pregabalin sustained-release tablets
Drug: Placebo

First Posted Date: 2024-04-25

Last Posted Date: 2024-04-30

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 358

Registration Number: NCT06383702

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Olaparib Tablet test formulation 150mg
Drug: Olaparib Tablet reference formulation 150mg
Drug: Olaparib Tablet test formulation 100mg
Drug: Olaparib Tablet reference formulation 100mg

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 102

Registration Number: NCT06360445

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: SYHX2011

First Posted Date: 2024-04-09

Last Posted Date: 2024-04-09

Lead Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT06354114

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy